Department of Ophthalmology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan.
College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
Int J Mol Sci. 2023 Apr 14;24(8):7285. doi: 10.3390/ijms24087285.
(1) To investigate the functional and anatomical outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with exudative age-related macular degeneration (AMD) with or without obstructive sleep apnea (OSA); (2) In total, 65 patients with AMD with or without OSA who received three consecutive doses of intravitreal anti-VEGF injections were enrolled. The primary outcomes-best-corrected visual acuity (BCVA) and central macular thickness (CMT)-were assessed at 1 and 3 months. Moreover, morphological changes observed through optical coherence tomography were analyzed; (3) In total, 15 of the 65 patients had OSA and were included in the OSA group; the remaining 50 patients were included in the non-OSA (control) group. At 1 and 3 months after treatment, BCVA and CMT had improved but did not differ significantly between the groups. More patients in the OSA group demonstrated subretinal fluid (SRF) resorption at 3 months after treatment than in the non-OSA group ( = 0.009). Changes in other imaging biomarkers, such as intraretinal cysts, retinal pigment epithelium detachment, hyperreflective dots, and ellipsoid zone disruptions, did not differ significantly between the groups; (4) Our results suggest that the BCVA and CMT outcomes 3 months after anti-VEGF treatment are similar between patients with and without OSA. Moreover, patients with OSA may exhibit superior SRF resorption. A large-scale prospective study is mandatory to evaluate the association between SRF resorption and visual outcomes in AMD patients with OSA.
(1) 研究抗血管内皮生长因子（anti-VEGF）治疗对伴有或不伴有阻塞性睡眠呼吸暂停（OSA）的渗出性年龄相关性黄斑变性（AMD）患者的功能和解剖学结局；(2) 共纳入 65 例伴有或不伴有 OSA 的 AMD 患者，这些患者接受了连续 3 次玻璃体内抗 VEGF 注射。在 1 个月和 3 个月时评估主要结局-最佳矫正视力（BCVA）和中心黄斑厚度（CMT）；此外，还分析了通过光学相干断层扫描观察到的形态变化；(3) 共有 15 例患者患有 OSA，被纳入 OSA 组；其余 50 例患者被纳入非 OSA（对照组）。治疗后 1 个月和 3 个月时，BCVA 和 CMT 均有所改善，但两组间无显著差异。治疗后 3 个月，OSA 组较非 OSA 组有更多的患者出现视网膜下液（SRF）吸收（ = 0.009）。其他成像生物标志物（如视网膜内液、视网膜色素上皮脱离、高反射点和椭圆体带破坏）的变化在两组间无显著差异；(4) 我们的结果表明，抗 VEGF 治疗后 3 个月，伴有和不伴有 OSA 的患者的 BCVA 和 CMT 结局相似。此外，OSA 患者可能表现出更好的 SRF 吸收。需要进行大规模前瞻性研究来评估 OSA 合并 AMD 患者的 SRF 吸收与视觉结局之间的关联。
